title: 99Tcm-LL1: a potential new bone marrow imaging agent.
abstract: LL1, a monoclonal antibody (MAb) to HLA Class-II-like antigen (li determinant) on the surface of B-lymphocytes, monocytes and histiocytes, was evaluated as an agent for bone marrow imaging. Six patients with diverse diseases (non-Hodgkin's lymphoma, n = 2; multiple myeloma, n = 1; polycythaemia vera, n = 1; lung cancer, n = 1; breast cancer, n = 1) were given low protein doses (< 1 mg) of 99Tcm (30 mCi) labelled Fab' of LL1. 99Tcm-sulphur colloid (SC) imaging was performed in three patients for comparison. Both planar and single photon emission tomographic images were acquired using Sopha gamma cameras. As early as 2 h post-MAb injection, excellent bone marrow images were achieved in all patients, demonstrating both normal or hyperproliferative marrow, as well as 'cold' bone marrow abnormalities such as radiation defects or cancer metastases. Similar to SC, relatively high uptake of LL1 was found in the liver and spleen. However, the bone marrow-to-liver and -spleen uptake ratios were approximately 19-fold higher (0.75 vs 0.04) and 6-fold higher (1.23 vs 0.22), respectively, with LL1 than with SC. The higher bone marrow uptake allowed clearly superior visualization of the thoracic spine when compared to SC. The mean T1/2 of blood and whole-body clearance were 0.4 and 66 h, respectively. The highest radiation absorbed doses (in cGy mCi-1) were observed in the spleen (0.47 +/- 0.24), kidneys (0.25 +/- 0.09) and liver (0.14 +/- 0.04). The bone marrow dose was only 0.05 +/- 0.02 cGy mCi-1. These results indicate that bone marrow imaging with 99Tcm-LL1 is feasible, and that LL1 may be a suitable alternative to SC because of better visualization of the lower thoracic spine. Potential applications include the improved detection of bone marrow metastases of solid tumours and the assessment of haematological disorders.
authors.affiliation: Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07103, USA.
authors.forename: M
authors.initials: M
authors.lastname: Juweid
authors.forename: R M
authors.initials: RM
authors.lastname: Dunn
authors.forename: R M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: A D
authors.initials: AD
authors.lastname: Rubin
authors.forename: H J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D001853:Bone Marrow / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D051379:Mice; D009101:Multiple Myeloma / Q000000981:diagnostic imaging*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011087:Polycythemia Vera / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection / Q000379:methods*; D013667:Technetium / Q000493:pharmacokinetics; D013671:Technetium Tc 99m Sulfur Colloid / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
chemical_list: D000911:Antibodies, Monoclonal; D013671:Technetium Tc 99m Sulfur Colloid; D013667:Technetium